Meitheal Pharmaceuticals said Thursday it launched a generic form of Bristol-Myers Squibb's (BMY) Abraxane in the US via an exclusive license and supply agreement with parent Hong Kong King-Friend Industry.

The single-dose protein-bound paclitaxel for injectable suspension is used to treat cancers, including metastatic breast and non-small cell lung cancers, the company said.

Price: 47.45, Change: +0.48, Percent Change: +1.01